Binge-Eating Disorder Treatment Market Size, Share and Growth Outlook, 2026

Binge-Eating Disorder Treatment Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Binge-Eating Disorder Treatment Market size is forecast to increase from $2.44 Billion in 2026 to $3.95 Billion in 2034 at a CAGR of 6.2% between 2026 and 2034.

The Binge-Eating Disorder Treatment market report provides detailed analysis and outlook of Binge-Eating Disorder Treatment segments including By Treatment Type (Pharmacotherapy, Psychotherapy and Behavioral Therapy, Nutritional Therapy and Counseling), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Specialty Clinics, Mental Health Centers, Psychiatric Rehabilitation Facilities), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Binge-Eating Disorder (BED) Treatment Industry Overview

Obesity Management Strategies Expand the Scope of BED Treatment

The Binge-Eating Disorder (BED) Treatment industry is evolving as healthcare providers increasingly recognize the strong relationship between obesity, metabolic dysfunction, and behavioral health disorders. Modern treatment frameworks are moving beyond traditional weight-based assessments and adopting a more comprehensive approach that considers psychological, metabolic, and behavioral factors. This shift has been reinforced by updated international clinical guidelines that redefine obesity as a multifactorial disease rather than a condition measured solely by body mass index. Following the resolution of supply constraints for glucagon-like peptide-1 (GLP-1) therapies, Novo Nordisk has accelerated its broader obesity care strategy, increasingly positioning semaglutide-based treatments within a framework that addresses obesity-related comorbidities, including binge-eating disorder. The growing integration of metabolic and behavioral health management is expanding therapeutic opportunities and encouraging more holistic treatment approaches for patients experiencing recurrent binge-eating episodes.

Neuro-Inflammatory Research Opens New Therapeutic Pathways

Scientific understanding of binge-eating disorder is becoming increasingly sophisticated as researchers investigate the biological mechanisms underlying compulsive eating behaviors and loss-of-control episodes. A growing body of evidence suggests that neuro-inflammatory pathways may play a role in behavioral and metabolic disorders, creating new opportunities for therapeutic innovation. Vyne Therapeutics has continued the clinical evaluation of VYN202, a BD2-selective oral BET inhibitor primarily being developed for immuno-inflammatory conditions. Although the program is not specifically focused on binge-eating disorder, the company’s broader research into BET protein modulation is attracting attention because of its potential relevance to metabolic and behavioral health applications. The exploration of neuro-inflammatory targets reflects a broader industry trend toward identifying novel biological pathways that could provide alternative treatment options for patients who do not respond adequately to conventional behavioral or pharmacological interventions.

Demand Grows for Non-Stimulant Treatment Approaches

The Binge-Eating Disorder treatment landscape is also being influenced by regulatory and clinical trends that favor safer and more targeted therapies. Historically, stimulant-based medications have played a significant role in managing behavioral disorders; however, concerns regarding cardiovascular risks and long-term tolerability have encouraged the search for alternative approaches. Throughout recent regulatory review cycles, the U.S. Food and Drug Administration’s central nervous system drug pipeline has demonstrated growing interest in non-stimulant therapies capable of addressing behavioral symptoms without the limitations associated with amphetamine-based treatments. This shift has stimulated increased investment in next-generation BED therapies designed to reduce loss-of-control eating behaviors while offering improved safety profiles. As research continues to uncover the neurological, inflammatory, and metabolic drivers of binge-eating disorder, pharmaceutical developers are focusing on innovative non-stimulant treatment strategies that support long-term disease management and improved patient outcomes.

Binge-Eating Disorder Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Binge-Eating Disorder Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Takeda Pharmaceutical (Vyvanse), Lundbeck, Eli Lilly and Company, Viatris (Mylan/Upjohn), Shire (Takeda), Acadia Healthcare, Universal Health Services (UHS), Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Orexigen Therapeutics. The Binge-Eating Disorder Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Binge-Eating Disorder Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Binge-Eating Disorder Treatment Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Binge-Eating Disorder Treatment companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Binge-Eating Disorder Treatment markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Binge-Eating Disorder Treatment Market Competitive Benchmarking and Company Analysis

Leading companies in Binge-Eating Disorder Treatment industry include- Takeda Pharmaceutical (Vyvanse), Lundbeck, Eli Lilly and Company, Viatris (Mylan/Upjohn), Shire (Takeda), Acadia Healthcare, Universal Health Services (UHS), Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Orexigen Therapeutics. The Binge-Eating Disorder Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Binge-Eating Disorder Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Binge-Eating Disorder Treatment market remains one of the strongest-performing segments in the country.
The US Binge-Eating Disorder Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Binge-Eating Disorder Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Binge-Eating Disorder Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Binge-Eating Disorder Treatment markets

Canada's strong Binge-Eating Disorder Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Binge-Eating Disorder Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Binge-Eating Disorder Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Binge-Eating Disorder Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Binge-Eating Disorder Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Binge-Eating Disorder Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Binge-Eating Disorder Treatment market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Binge-Eating Disorder Treatment sales through 2034

France Binge-Eating Disorder Treatment companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Binge-Eating Disorder Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Binge-Eating Disorder Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Binge-Eating Disorder Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Binge-Eating Disorder Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Binge-Eating Disorder Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Binge-Eating Disorder Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Binge-Eating Disorder Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Binge-Eating Disorder Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Binge-Eating Disorder Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Binge-Eating Disorder Treatment Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Binge-Eating Disorder Treatment Market Segmentation

By Treatment Type
Pharmacotherapy
Psychotherapy and Behavioral Therapy
Nutritional Therapy and Counseling
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Specialty Clinics
Mental Health Centers
Psychiatric Rehabilitation Facilities
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online

Top Companies in Binge-Eating Disorder Treatment Industry

Takeda Pharmaceutical (Vyvanse)
Lundbeck
Eli Lilly and Company
Viatris (Mylan/Upjohn)
Shire (Takeda)
Acadia Healthcare
Universal Health Services (UHS)
Sunesis Pharmaceuticals
Jazz Pharmaceuticals
Orexigen Therapeutics

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025